Praxis Precision Medicines stopped its Phase 2/3 EMBOLD trial early after an interim analysis showed robust efficacy for relutrigine in developmental and epileptic encephalopathies, prompting a sharp stock rally. The company plans to use the dataset to support regulatory discussions with FDA. Investigators and investors flagged the early halt as a significant clinical milestone for a difficult-to-treat population, while analysts noted the company must still complete long-term safety and durability follow-up to underpin a filing and payer discussions.